Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Mol Cancer Res. 2017 Jan 4;15(4):478–488. doi: 10.1158/1541-7786.MCR-16-0337

Figure 5. OSM-induced mesenchymal/CSC plasticity requires activated STAT3.

Figure 5

(A) HPAC cells were treated with recombinant OSM, Ruxolitinib, or a combination of both for four hours. Western blot (upper panel) and qRT-PCR (lower panel) were performed as indicated. (B–D) HPAC cells were treated with recombinant OSM, Ruxolitinib, or a combination of both for 8 days. Flow cytometry (B), qRT-PCR (C) and Western blot analysis (D) were performed as indicated. The percentage of CD24LOW/CD44HI cells is indicated by the number below the flow cytometry scan in panel B. (E) Migration of HPAC cells treated as indicated was assessed using a live cell IncuCyte Zoom imaging system. The graph (left panel) and pictures (right panel) show the number of migrated cells at the indicated times; error bars represent ± SEM for a representative experiment performed in triplicate; a 2-way ANOVA was performed in order to determine significance; **** = p-value ≤ 0.001.